Mexico has approved the world’s first vaccine to prevent dengue.
The dengue vaccine, Dengvaxia, will be developed and marketed by Sanofi, and will prevent disease caused by all four dengue virus serotypes. The drug is likely to be available early next year in Mexico.
The approval was granted by the Federal Commission for the Protection against Sanitary Risks, based on a clinical development program involving over 40,000 people of different ages in 15 countries.
“Today, with this first marketing authorization ofDengvaxia®, we have achieved our goal of making dengue the next vaccine-preventable disease. This is a historic milestone for our company, for the global public health community and, most importantly, for half the world’s population who lives at risk of dengue,” states Olivier Brandicourt, chief executive officer of Sanofi.
According to the World Health Organization (WHO), dengue is the fastest growing mosquito-borne disease in the world today. In addition to Mexico, dengue is a growing health threat to many other tropical and subtropical countries in Latin America and Asia.
Sanofi said in a statement that it plans to introduce Dengvaxia in other endemic countries. The company added that regulatory review processes for the drug are continuing in these countries.
Further, Sanofi said that it already started manufacturing of Dengvaxia at vaccine facilities in France. The company did not disclose a price tag for the drug.
According to the WHO, dengue is causing nearly 400 million infections every year. The dengue is growing worldwide due to factors such as increased urbanization, mobility of populations and climate changes.
“In the last 50 years dengue has spread from being present in a handful of countries to being endemic in 128 countries, where about 4 billion people live, and dengue incidence has likewise increased 30-fold in this time period,” according to a statement.